Mavacamten Use Can Reduce Need for Septal Reduction Therapy in oHCM

Results of the 56-week VALOR-HCM trial provide new insight into the effects of mavacamten in patients with highly symptomatic obstructive hypertrophic cardiomyopathy referred for septal reduction therapy.

Related Keywords

Roberto Bonow ,Jamese Udelson ,Amy Sehnert ,Milind Desai ,Vascular Thoracic Institute At Cleveland Clinic ,Bristol Myers Squibb ,American College Of Cardiology Heart Association ,European Society Of Cardiology ,European Society ,Thoracic Institute ,American Heart Association ,Confidence Interval ,Heart Failure Clinical Development ,Bristol Myers ,Mitigation Strategy ,Septal Reduction ,Term Efficacy ,Esc Congress 2023 ,Cardiology ,Hypertrophic Cardiomyopathy ,Johcm ,Mavacamten ,Camzyos ,